A highly immunogenic fragment derived from Zaire Ebola virus
glycoprotein elicits effective neutralizing antibody.
Infectious disease has only recently been recognized as a major threat to the survival of Endangered chimpanzees and Critically Endangered gorillas in the wild. One potentially powerful tool, vaccination, has not been deployed in fighting this disease threat, in good part because of fears about vaccine safety. Here we report on what is, to our knowledge, the first trial in which captive chimpanzees were used to test a vaccine intended for use on wild apes rather than humans. We tested a virus-like particle vaccine against Ebola virus, a leading source of death in wild gorillas and chimpanzees. The vaccine was safe and immunogenic. Captive trials of other vaccines and of methods for vaccine delivery hold great potential as weapons in the fight against wild ape extinction.
Pyridinyl imidazole inhibitors of p38 MAP kinase impair
viral entry and reduce cytokine induction by Zaire ebolavirus in human
Filovirus infections cause fatal hemorrhagic fever
characterized by the initial onset of general symptoms before rapid progression
to severe disease; the most virulent species can cause death to susceptible
hosts within 10 days after the appearance of symptoms. Before the advent of
monoclonal antibody (mAb) therapy, infection of nonhuman primates (NHPs) with
the most virulent filovirus species was fatal if interventions were not
administered within minutes. A novel nucleoside analogue, BCX4430, has since
been shown to also demonstrate protective efficacy with a delayed treatment
start. This review summarizes and evaluates the potential of current
experimental candidates for treating filovirus disease with regard to their
feasibility and use in the clinic, and assesses the most promising strategies
towards the future development of a pan-filovirus medical countermeasure.
J Antimicrob Chemother. 2014 Aug;69(8):2123-31. doi: 10.1093/jac/dku091. Epub 2014 Apr 7.